Amgen's stock dropped in premarket trading despite positive Phase 2 study results for MariTide, an experimental weight-loss drug. The study showed an average 20% weight loss after 52 weeks, with potential for further weight loss beyond.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing